Maravai LifeSciences Holdings, Inc.

Equities

MRVI

US56600D1072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
11.05 ^USD	+0.91%		-1.34%	+68.70%

May. 15	Transcript : Maravai LifeSciences Holdings, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 03:35 PM
May. 09	UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating	MT

Maravai LifeSciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 08, 2024 at 04:05 pm EDT

Maravai LifeSciences Holdings, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 64.18 million compared to USD 79.03 million a year ago. Net loss was USD 12.08 million compared to USD 0.067 million a year ago.

Basic loss per share from continuing operations was USD 0.09.

Latest news about Maravai LifeSciences Holdings, Inc.

Transcript : Maravai LifeSciences Holdings, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 03:35 PM	May. 15
UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating	May. 09	MT
Baird Adjusts Price Target on Maravai LifeSciences to $10 From $8, Keeps Outperform Rating	May. 09	MT
Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC Reports Q1 Revenue $64.2M, vs. Street Est of $60.5M	May. 08	MT
Transcript : Maravai LifeSciences Holdings, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Maravai LifeSciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024	May. 08	CI
Maravai LifeSciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego	Apr. 18	MT
Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target	Apr. 10	MT
RBC Raises Price Target on Maravai LifeSciences Holdings to $15 From $14, Keeps Outperform Rating	Apr. 08	MT
Transcript : Maravai LifeSciences Holdings, Inc. Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-19-2024 02:15 PM	Mar. 19
Sector Update: Health Care Stocks Rise in Late Afternoon	Feb. 23	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	Feb. 23	MT
Top Midday Gainers	Feb. 23	MT
Sector Update: Health Care	Feb. 23	MT
Maravai LifeSciences Shares Surge After Price Target Raises, Q4 Beat	Feb. 23	MT
UBS Adjusts Maravai LifeSciences Price Target to $6.50 From $6, Maintains Neutral Rating	Feb. 23	MT
Stifel Trims Price Target on Maravai LifeSciences to $10 From $11, Maintains Buy Rating	Feb. 23	MT
Traders Await Fresh Cues After Nvidia-Fueled Rally as US Equity Futures Inch Higher Pre-Bell	Feb. 23	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	Feb. 23	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday	Feb. 23	MT
RBC Raises Price Target on Maravai LifeSciences Holdings to $14 From $12, Cites 'Clean' Q4, Keeps Outperform Rating	Feb. 23	MT
Top Premarket Gainers	Feb. 23	MT
Maravai LifeSciences' Q4 Adjusted Earnings, Revenue Decline	Feb. 23	MT
Transcript : Maravai LifeSciences Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22

Chart Maravai LifeSciences Holdings, Inc.

Duration

Period

Chart Maravai LifeSciences Holdings, Inc.

More charts

Company Profile

Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.

Sector

Biotechnology & Medical Research

Calendar

05:30pm - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Maravai LifeSciences Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.05 USD

Average target price

10.42 USD

Spread / Average Target

-5.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
MARAVAI LIFESCIENCES HOLDINGS, INC.	+68.70%	1.47B
EXACT SCIENCES CORPORATION	-27.70%	9.87B
IOVANCE BIOTHERAPEUTICS, INC.	+27.06%	2.89B
GUARDANT HEALTH, INC.	-16.78%	2.75B
BGI GENOMICS CO., LTD.	-15.31%	2.13B
VERACYTE, INC.	-21.41%	1.65B
CAREDX, INC	+29.75%	811M
SEEGENE, INC.	-5.02%	733M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.39%	510M
CURIOX BIOSYSTEMS CO., LTD	+1.59%	300M

Bio Diagnostics & Testing